Effects of short-term estradiol and norethindrone acetate treatment on the breasts of normal postmenopausal women.

Objective: The aim of this study was to evaluate among postmenopausal women the effects of a 3-month treatment with estradiol (E-2) alone or in combination with norethindrone acetate (NA) on expression of hormone receptors and proliferation in the breast as well as on lipids and climacteric symptoms. Methods: Sixty healthy postmenopausal women were computer-randomized into two groups, with one group receiving 1 mg of E-2 and the other group receiving 1 mg of E-2 and 0.5 mg of NA daily for 12 weeks. Before and after treatment, middle-needle biopsies were obtained for histology and investigation of the expression levels of estrogen receptors (ERs; ER-alpha and ER-beta), progesterone receptors (PRs; PR-A and PR-B), androgen receptor (AR), the proliferation marker Ki67, and collagen. Climacteric symptoms were recorded, and serum was collected to measure lipoprotein levels. Results: Fifty-six women finished the 12-week study. Proliferating cells (Ki67-positive) were very rare in all but a few of the untreated women. There were proliferating cells in both E-2- and E-2/NA-treated groups; however, these were not widespread and limited to nests of cells that amounted to 2% of the total epithelial cells. Some of these nests were positive for human epithelial growth factor receptor 2. Treatments caused no marked changes in the expression of ER-alpha, ER-beta, or AR. However, both treatments resulted in an increase in PR-A and PR-B expressions. The presence of collagen was clearly associated with a mammographic diagnosis of dense breasts, but neither hormone treatment affected breast density. Both E-2 and E-2/NA treatments were effective in relieving hot flashes and sweating without adverse effects on blood pressure, weight, and liver, kidney, and thyroid functions. A decrease in cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol was induced by E-2/NA but not by E-2. Conclusions: This short-term prospective study shows that E-2 and estrogen-progestogen treatment can upregulate PRs but do not significantly affect ERs, AR, proliferation, or breast density.